Cardiol Therapeutics Inc Class A (CRDL) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.292x

Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) has a cash flow conversion efficiency ratio of -0.292x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.23 Million ≈ $-3.78 Million USD) by net assets (CA$17.88 Million ≈ $12.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CRDL defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Cardiol Therapeutics Inc Class A - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Cardiol Therapeutics Inc Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cardiol Therapeutics Inc Class A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cardiol Therapeutics Inc Class A ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Jyong Biotech Ltd. Ordinary Shares NASDAQ:MENS	0.041x
Kelly Partners Group Holdings Ltd AU:KPG	0.259x
Red Planet Indonesia Tbk JK:PSKT	0.006x
Satellos Bioscience Inc. TO:MSCL	-0.266x
Menang Corporation (Malaysia) Bhd KLSE:1694	0.058x
Yen Sun Technology TWO:6275	0.086x
Caravel Minerals Ltd AU:CVV	-0.375x
Nicola Mining Inc. American Depositary Shares NASDAQ:NICM	-3.612x

Annual Cash Flow Conversion Efficiency for Cardiol Therapeutics Inc Class A (2017–2025)

The table below shows the annual cash flow conversion efficiency of Cardiol Therapeutics Inc Class A from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Cardiol Therapeutics Inc Class A (CRDL) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CA$17.88 Million ≈ $12.93 Million	CA$-23.85 Million ≈ $-17.26 Million	-1.334x	-31.66%
2024-12-31	CA$24.73 Million ≈ $17.89 Million	CA$-25.06 Million ≈ $-18.13 Million	-1.013x	-13.68%
2023-12-31	CA$28.25 Million ≈ $20.43 Million	CA$-25.18 Million ≈ $-18.22 Million	-0.891x	-70.96%
2022-12-31	CA$52.20 Million ≈ $37.76 Million	CA$-27.22 Million ≈ $-19.69 Million	-0.521x	-68.80%
2021-12-31	CA$76.24 Million ≈ $55.15 Million	CA$-23.55 Million ≈ $-17.04 Million	-0.309x	+55.37%
2020-12-31	CA$13.27 Million ≈ $9.60 Million	CA$-9.19 Million ≈ $-6.64 Million	-0.692x	+10.76%
2019-12-31	CA$14.67 Million ≈ $10.61 Million	CA$-11.38 Million ≈ $-8.23 Million	-0.776x	-58.59%
2018-12-31	CA$22.27 Million ≈ $16.11 Million	CA$-10.89 Million ≈ $-7.88 Million	-0.489x	-8.02%
2017-12-31	CA$2.85 Million ≈ $2.06 Million	CA$-1.29 Million ≈ $-934.75K	-0.453x	--

About Cardiol Therapeutics Inc Class A

TO:CRDL Canada Drug Manufacturers - Specialty & Generic

Market Cap

$118.76 Million

CA$164.17 Million CAD

Market Cap Rank

#18638 Global

#620 in Canada

Share Price

CA$1.47

Change (1 day)

+0.00%

52-Week Range

CA$1.28 - CA$2.23

All Time High

CA$8.13